~~<i id='84C210D1E1'><strike id='84C210D1E1'><tt id='84C210D1E1'><pre id='84C210D1E1'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：focus 2025-10-02 08:27:45 Page View：63227

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anavex keeps shifting the goalposts in its clinical trials
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

What to know about Virgin Galactic's 1st mission taking paying customers to space

1:42TheVirginGalacticSpaceShipTwospaceplaneUnityreturnstoearthaboveSpaceportAmerica,nearTruthandCons

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

AstraZeneca to buy developer of next

AlastairGrant/APLONDON—AstraZenecasaidTuesdayitwouldacquireFusionPharmaceuticalsinadealworthmorethan